<DOC>
	<DOCNO>NCT02324335</DOCNO>
	<brief_summary>Oral Mucositis ( OM ) painful debilitate side effect many drug/radiation regimen use treat cancer . This study examine investigational drug brilacidin possible application prevention oral mucositis patient undergoing chemoradiation treatment head neck cancer .</brief_summary>
	<brief_title>Study Effects Brilacidin Oral Rinse Radiation-induced Oral Mucositis Patients With Head Neck Cancer</brief_title>
	<detailed_description>This study examine whether daily oral rinse solution contain brilacidin prevent occurrence OM lessen severity OM occur . Patients use oral rinse 3 time daily seven week chemoradiation head neck cancer .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>1 . Willing able read , understand sign inform consent form ( ICF ) 2 . Have recently diagnose ( within previous 6 month ) pathologically confirm , nonmetastatic squamous cell carcinoma oral cavity , oropharynx , hypopharynx , supraglottic larynx treat CRT therapy first line nonsurgical treatment . Scans ( CT , PET , and/or MRI ) obtain within 120 day prior consent screening use determine subject 's eligibility . 3 . Have plan receive continuous course conventional external beam irradiation deliver intensitymodulated radiotherapy ( IMRT ) single daily fraction 2.0 Gy 2.2 Gy cumulative radiation dose ≥55 Gy ≤72 Gy . Planned radiation treatment field must include least two oral site ( buccal mucosa , floor mouth , ventral/lateral tongue , soft palate ) . [ Note : independent RTQA consultant must confirm plan radiation treatment meet protocol criterion ] 4 . Have plan receive standard cisplatin chemotherapy regimen administer weekly ( 3040 mg/m2 ) approximately every 21 day ( 80100 mg/m2 ) 5 . Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . However , potential subject ECOG 3 may enrol provided condition preclude perform action require study participation ( e.g. , open medication bottle , swish oral rinse spitting , complete participate completion daily diary FACTH &amp; N form ) . 6 . Have adequate hematopoietic , hepatic , renal function screen visit 7 . Urine serum pregnancy test : negative female patient childbearing potential 8 . Agree utilize medically accept method birth control study participation 90 day follow last treatment study drug female subject childbearing potential male subject opposite sex partner child bear potential . 9 . Males female age ≥18 year day consent . 1 . Has tumor ( ) lips , sinus , salivary gland , nasopharynx , glottic larynx , subglottic larynx unknown primary tumor 2 . Has metastatic disease ( M1 ) Stage IV C 3 . Has prior radiation head neck 4 . Plan treat cetuximab ( Erbitux® ) 5 . Planned use cisplatin induction chemotherapy . 6 . Has history malignant tumor within last 5 year , except non melanoma skin cancer situ cervical carcinoma curatively excise 7 . Has major surgical procedure , HNC , significant traumatic injury within 4 week prior initiation RT ; anticipation need major surgical procedure course study 8 . Has incompletely heal site dental extraction 9 . Has 12lead ECG obtain screen visit show medically significant abnormality ( y ) ( e.g . leave bundle branch block , frequent premature ventricular contraction , QTc interval prolongation &gt; 450 msec male &gt; 470 msec female ) 10 . Has untreated hypertension hypertension treatment meet protocol definition . 11 . Has active infectious disease undergoing systemic treatment exclude oral candidiasis 12 . Has oral mucositis ( severity ) prior initiation radiation therapy 13 . Has diagnosis immunosuppressive illness condition require chronic immunosuppression 14 . Has know seropositivity HIV hepatitis C antibody , know hepatitis B surface antigen positive ( test serologic marker require enrollment protocol ) 15 . Use investigational agent within 30 day randomization 16 . Is pregnant breastfeed 17 . Has know allergy intolerance brilacidin , cisplatin carboplatin 18 . Has inability give inform consent comply study requirement 19 . Has condition prior therapy opinion Investigator would make patient unsuitable study and/or unable comply requirement followup visit . 20 . Is unwilling unable agree swish spit study oral rinse three time per day study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Oral Mucositis</keyword>
	<keyword>Brilacidin</keyword>
	<keyword>Chemoradiation</keyword>
</DOC>